Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 23, 2026

Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know

View original at finance.yahoo.com
Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know Tenable, PagerDuty, and HubSpot Shares Are Falling, What You Need To Know What Happened?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The sector-wide software selloff was indiscriminate, driven mechanically by the index weight of Alphabet and Microsoft.

    60% confidence
  • Salesforce is a Buy on valuation.

    60% confidence
  • The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

    60% confidence
  • Adobe has not traded this cheaply on an earnings basis in over a decade.

    60% confidence
  • AI is compressing demand for traditional IT services, directly reducing billable hours at Accenture.

    60% confidence
  • Market fear persists that AI agents will erode the subscription model underpinning traditional enterprise software economics.

    60% confidence
  • Salesforce is acquiring m3ter precisely to monetize AI agent actions rather than seats, positioning itself for a usage-based revenue transition.

    60% confidence
  • Salesforce is a Rule-of-40 company, retiring 10% of its shares through a $25 billion buyback and carries the largest AI revenue line in the CRM category.

    60% confidence
  • Software stocks may remain in the penalty box until companies can prove AI revenue scales faster than it erodes the legacy subscription base.

    60% confidence
  • The market is pricing AI cannibalization of legacy software as if it has already happened, but income statements may indicate otherwise.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com